Artelo Biosciences Reports Third Quarter 2026 Financial Results and Business Update

Nov 13, 2026, 9:16 AM ETResultsRead the original at globenewswire.com

Neutral

Artelo reported a $1.8 million quarterly loss and $4.4 million in cash and investments, alongside animal weight-loss results, patent steps and a glaucoma study start. The animal work is early, and these developments do not clearly change the company's prospects.

ARTL · Artelo Biosciences

AI read · Neutral

The AI's read

The animal results and patent steps add support for ART27.13, and the glaucoma study has begun. But the obesity results came from animals, not people. Progress is still early, and the reported loss and cash balance point to limited resources. These facts leave the company's prospects balanced.

Get alerts for ARTL

Follow Artelo Biosciences (ARTL) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for ARTL

Free on the App Store and Google Play, or on the web.